Although anti-IL-1 treatment is recommended for all phenotypes and is known to be effective throughout the complete CAPS severity spectrum [51], it is still important to distinguish among the subphenotypes, particularly in the moderate to severe CAPS phenotypes, because more intensive treatment is necessary to achieve remission and to prevent organ damage [52,53,54]. Here, IL1B is linked to cryopyrin-associated periodic syndrome.